Navigation Links
Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
Date:1/9/2012

NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells (CSCs), today announced that Eric K. Rowinsky, M.D. will join the Company as Executive Vice President, Chief Medical Officer and Head of Research and Development. Dr. Rowinsky will oversee the development and registration efforts for the Company's two clinical stage drug candidates, SL-401 and SL-701, as well as its preclinical pipeline.

"I am very excited to join Stemline at such an important time for the Company," said Dr. Rowinsky. He continued, "Not only is the Company's clinical stage pipeline extremely unique compared to other therapeutics in development, but both SL-401 and SL-701 are demonstrating objective anti-tumor activity in several malignancies that represent important unmet medical needs. I look forward to developing these novel agents to their fullest potential, advancing Stemline's programs towards potential global registration, and, in doing so, hopefully improving the lives of people with a variety of malignancies."

Ivan Bergstein, Stemline's Chief Executive Officer, said, "Dr. Rowinsky brings a wealth of drug development experience to the Stemline team and we look forward to his contribution and leadership in advancing our pipeline forward."

Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs from preclinical to regulatory approval. Among his many endeavors before joining Stemline was that of Executive Vice President and Chief Medical Officer for Imclone Systems, Inc., where he led the FDA approval of Erbitux® for head and neck and colorectal cancers, and advanced eight other monoclonal antibodies through clinical development. Before joining Imclone, Dr. Rowinsky was the Director of the Institute of Drug Development ("IDD") at the Cancer Therapy and Research Center. In addition,
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...   Memorial Hermann Health System and The ... a new partnership to provide a new level of specialized ... in the greater Houston area. ... exclusive provider of professional breast radiology services for five of ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... ANGELES , Aug. 21, 2014 The spinal ... of the human body. Signals carried to and from the ... motor skills and nervous system. Injury or ailment here can ... or with a loss of control over their body. Though ... on a person,s life, there are more options available to ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... 2011 Reportlinker.com announces that a new market ... Hospital MRI (Magnetic Resonance Imaging/Tomography) Census ... This is the most comprehensive European market report ... (General Radiology, Mammography, R&F, Angiography, CT, MRI,) and ...
... PITTSBURGH, Jan. 20, 2011 Mylan Inc. (Nasdaq: ... Laboratories Limited has received tentative approval from the U.S. ... Plan for AIDS Relief (PEPFAR) for its New Drug ... mg. The NDA is based on the reference listed ...
Cached Medicine Technology:Reportlinker Adds Hospital MRI (Magnetic Resonance Imaging/Tomography) Census 2Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Legal ... system created by Greg Marks has been generating a ... this month. The commotion surrounding the new product has ... investigative review. , “In recent years the ... software systems, commonly referred to as robots or ‘bots,'” ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final ... of ProIntro Vol.3, a customizable title tool for FCPX ... just by dragging ProIntro Vol.3 in their timeline" says Christina ... definite time saver and i think our users will agree" ... designed titles made with Final Cut Pro X users in ...
(Date:8/23/2014)... Teen substance abuse ranks as one of ... NC. Countless adolescents throughout North Carolina struggle with a drug ... never receive professional rehab due to a lack of information ... help. Troubled Teens Holly Springs is a helpline designed to ... teenage alcohol abusers in Wake County who are seeking ...
(Date:8/22/2014)... 2014 On Friday, Aug. 22, Liberty ... Health Sciences , hosting a ceremony in its courtyard ... government and public welfare. , The 162-member inaugural class ... (LUCOM) joined Liberty staff, faculty, and community leaders ... the new medical school. Classes began on Monday, Aug. ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2
... A-I ratio is not a better predictor of coronary ... total cholesterol and HDL-C, according to a study in ... instruments and guidelines for coronary heart disease (CHD) prevention ... cholesterol, or both for CHD risk assessment. But in ...
... scale, multiethnic study of its kind, researchers at UCLA ... known as cytokines as a cause of Type 2 ... biological markers that may be used to more accurately ... , Reporting in the August 15 issue of the ...
... improve their understanding of the potential increased risk of ... study conducted by researchers from The Childrens Hospital in ... New Haven, CT. , Like many radiology departments around ... exposure to children caused by increased usage of CT. ...
... Columbia University Medical Center researchers have demonstrated using ... was increased in stroke and traumatic brain injury ... rehabilitative treatment that helps these patients recover lost ... the peer-reviewed journal Neurorehabilitation and Neural Repair on ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
... antiplatelet drugs (e.g., acetylsalicylic acid) are key therapeutic ... this study, Joseph Delaney MSc, Dr. James Brophy ... cases with a diagnosis of gastrointestinal bleeding and ... documented a 46-fold increase in the rate of ...
Cached Medicine News:Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 3Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2Health News:Vision restoration therapy shown to improve brain activity in brain injured patients 2
Take Performance to a Higher Level....
A fusion of first class deliverability, acute angiographic results and excellent versatility....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Galaxy IVUS Imaging System simplifies the process of intracardiac echo while delivering accurate, real-time diagnostic information in less time with less work. (Ultra ICE catheter compatible)...
Medicine Products: